Jason and Mani: welcome aboard!
Following our move toward our internal biological resources we have hired two biologists: Jason…
We are creating novel drug substances that will take advantage of the unique properties of nature inspired lipids and combine the target areas indicated in the diagram: the anticancer, immune enhancing, and tumor selective drug delivery.
Our approach takes advantage of the function of lipids in biological systems. Once considered as passive structural components of membranes, it is now widely recognized that in addition to controlling stability and permeability, lipids (particularly phospholipids) can influence metabolism and a wide variety of cellular signaling pathways. Nature inspired phospholipid molecules represent intriguing opportunity for developing novel drug candidates with great potential to achieve multi-level effects on human health while maintaining low toxicity.
Killing cancerous cells is essential to developing effective treatments. It is becoming more appreciated that lipids play an important function in cancer etiology. For instance phospholipids have been shown to impact or inhibit carcinogenic processes including cell growth, cell migration and metastasis formation. Phospholipids have also shown the ability to inhibit kinase pathways important in cancer
Inhibiting the growth of tumor cells while sparing normal cells is essential to developing safe therapies. As a result of amplified proliferation, cancerous cells often have increased rates of metabolism.
Because lipids are essential for cell growth, research has shown these compounds can selectively accumulate in cancerous cells, thereby providing the opportunity for targeted drug delivery with improved safety.
The immune system plays a key role in keeping us healthy. Phospho lipids modulate a great number of immune related events, such as lymphocyte proliferation, cytokine production, as well as phagocytosis. The biological processes are important for several autoimmune diseases. Moreover, these biochemical processes are becoming to be recognized as key targets for improved immuno- oncology treatments.
Machavert is a bio-pharmaceutical company that develops new, first-in-class therapeutics that will harness the power of the human body to treat cancer and autoimmune diseases. Our approach takes advantage of nature-inspired non-toxic substances that inhibit cancer growth, interact with the human immune system or enhance the targeting and efficacy of other therapeutics.
Our primary goal is to improve the length and the quality of life of patients suffering from life threatening diseases such as pancreatic cancer. Machavert currently focuses on preclinical research and development to build a robust portfolio of drug candidates for clinical trials.
Our leading drug candidate, designated as MP1, is a broad-spectrum lipid based product that exhibits potent anti-cancer efficacy as well as high degree of tolerability in animal models. In addition to progressing MP1 into advanced animal and efficacy studies which will support human clinical trials, we are developing several next generation drug candidates to be employed as tumor specific kinase inhibitors, immuno-stimulants or tumor specific drug delivery agents.
We are a group of passionate innovators with multidisciplinary expertise; focused on the challenge to create new ways to treat cancer and other diseases with unmet medical needs.
Cofounder and Chief Executive Officer
Jakub co-founded Machavert and acts as Chief Executive Officer. Prior Machavert, Jakub has worked as a scientist at numerous research organizations such as Argonne National Laboratory, IL, University of Gothenburg in Sweden and University of Liverpool in the UK. Jakub has also worked and was closely involved with our partner company Areko as a director and advisor to the executive team. Jakub graduated and holds Ph.D. from the Institute of Chemical Technology in Prague.
Chief Science Officer
As the Chief Science Officer, Greg is responsible for creating and implementing of our scientific vision and overseeing R&D operations. Greg has over 15 years of experience in medicinal chemistry and has worked at research positions both at small and large organizations such as Abbot Laboratories, Array Biopharma and lastly as an Associate Director at the Colorado Center for Drug Discovery at Colorado State University. Greg has been involved in almost all aspects of preclinical drug discovery and has worked in the areas of cancer, inflammation, pain and anti-virals. Greg authored several research papers and patent applications, graduated from the University of Wyoming, obtained Ph.D. from Colorado State University and was an American Cancer Society post-doctoral fellow and the University of Texas, Austin.
Chemist, VP R&D Operations
Colleen is at the core of the synthesis and design of new molecules at our drug discovery chemical lab and also acts as our Vice President of R&D operations. She is a medicinal chemist with a 10+ years of experience most recently at Ironwood Pharmaceuticals, Cambridge, MA as well as other research organizations such as ArQule, Bayer, and Infinity Pharmaceuticals. She has authored several granted patents and patent applications, and has compounds that have moved forward into FDA trials. Colleen holds a B.S. in Chemistry from Salem State University, MA.
Luca is our Chief Chemist and is responsible for synthesis and design of new molecules at our drug discovery chemical lab. Prior joining Machavert, Luca was a research assistant in the lab of Prof. Marvin Caruthers at the University of Colorado at Boulder where he published several scientific papers and patent applications in the field of biochemistry, co-authored with Agilent Technologies. Luca holds a Ph.D. from the University of Naples Federico II in Italy.
As a Scientist, Mani is responsible for research in biology and molecular biology focused on our compounds and their mechanism of action. Mani is an experienced investigator with 10+ years of cutting edge research focused on phospholipids and their cell biology related to autoimmune and other diseases. Prior joining Machavert, he has worked over 10 years at the Department of Medicine at National Jewish Health in Denver and published several scientific papers. Mani graduated from Madurai Kamaraj University and obtained his Ph.D. from Indian Institute of Science in India.
Jason is a Senior Scientist leading our biology and molecular biology research programs related to cancer and immunology. Jason has 10+ years of experience with cutting edge cancer research and is now applying this knowledge to drug discovery and pharmacology. He has previously worked in cancer research at the University of Colorado Cancer Center and the University of Pittsburgh. Jason has authored numerous research papers, received many awards and acquired a number of externally funded grants. Jason holds degrees from the University of Wisconsin-Stevens Point (B.S) and the University of Iowa (Ph.D.).
National Jewish Health, Denver
Dennis is a professor at National Jewish Health in Denver. His major research areas of interests are phospholipid transport processes in eukaryotic cells and pulmonary surfactant proteins – structure and function. Dennis acts as a general science advisor regarding phospholipid function in cells as well as design of new avenues toward employing phospholipids in treatments of autoimmune diseases as well as cancer.
Charles University, Prague
Pavla is an associate professor at Charles University in Prague. Pavla is an expert in biology and pharmacology and animal models of human diseases such as cancer. Pavla helps us with design of in-vivo cancer models and pharmacokinetics.
Stanislav is a co-founder of Machavert and provides advice on long-term strategy and holding management. Throughout his professional career he held several executive positions in leading companies including Societe Generale and Vodafone. Stanislav’s main focus is on the areas of company strategy creation, supply chain management and most recently global asset management / cost optimization. He currently resides in Luxembourg, and previously lived in the Czech Republic, China and Germany. Stanislav holds an MBA in Banking and Finance.
Cofounder and CEO of Invia (Czech Republic), Serial entrepreneur
Michal cofounded Machavert and is responsible for investor relations and as CFO is responsible for controlling and budgeting. Michal actually holds the CEO position in biggest online travel agency in CEE – Invia.cz, a.s. and as investor participates in multiple other projects in Czech Republic, Poland and Russia. Michal graduated at the University of Economics in Prague.
Cofounder and CEO of Areko, Czech Republic
Pavel is cofounder and CEO of Areko, Czech Republic. Pavel ensures smooth cooperation between Areko and Machavert and advises Machavert in both business aspects as well as R&D matters related to natural phospholipid processing and manufacturing. Prior Areko Pavel held executive positions in a major Czech medical products manufacturer Chemopharma; including CTO and CFO. Pavel graduated at Institute of Chemical Technology in Prague.
Radek is a serial entrepreneur and investor. Radek currently acts as CEO of several Universities and educational institutions in the Czech Republic and manages a number of other entrepreneurial activities. Radek cofounded Machavert and provides general business advice regarding seeking of funding as well as administrative tasks. Radek graduated at the University of Economics in Prague.
We have partnered with leading firms to provide us with additional expertise, guidance and resources.
Areko is a biotech company based in the Czech Republic and founded in 1999. Machavert builds on the 15+ years of experience of Areko in the field of biologically active phospholipids. Areko provides know-how related to R&D and manufacturing of phospholipids as well as guidance and R&D resources to Machavert.